A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 [tipifarnib] in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer

Trial Profile

A Phase I, Maximum Tolerated Dose (MTD) Trial to Determine the Safety and Pharmacokinetics of Chronic Oral Administration of Farnesyl Transferase Inhibitor R115777 [tipifarnib] in Combination With Gemcitabine in Subjects With Advanced Incurable Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2012

At a glance

  • Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top